Skip to main content
EJNMMI Research

Table 2 SUVmax at before, during, and after neoadjuvant chemotherapy depending on the event

From: Early response monitoring of neoadjuvant chemotherapy using [18F]FDG PET can predict the clinical outcome of extremity osteosarcoma

 

Parameter

Mean ± SD

p value

All patients

SUV0

9.1 ± 5.1

 

SUV1

5.9 ± 3.4

< 0.001*,‡

SUV2

4.9 ± 3.2

< 0.001†,‡

Non-event group

SUV0

9.2 ± 5.4

 

SUV1

5.7 ± 3.4

< 0.001*,‡

SUV2

4.6 ± 3.4

< 0.001†,‡

Event group

SUV0

8.7 ± 4.1

 

SUV1

6.8 ± 2.3

0.017*,‡

SUV2

5.9 ± 2.5

0.003†,‡

  1. SUV0 SUVmax of baseline [18F]FDG PET before neoadjuvant chemotherapy, SUV1 SUVmax for interim [18F]FDG PET after 1 cycle of chemotherapy, SUV2 SUVmax of postchemotherapy [18F]FDG PET, SD standard deviation
  2. *p value between SUV0 and SUV1
  3. †p value between SUV0 and SUV2
  4. ‡Statistically significant with p value < 0.05
Back to article page